Loading your workspace…
All markets
Hantavirus vaccine in 2026?
Foretrace AI research
Understand the odds. Examine the reasoning.
Polymarket shows market prices. Foretrace adds AI probability estimates, opposing evidence and a price-dependent outcome or pass decision for each open market.
Choose a market to analyze 1 open question · Evidence required
24h volume$82.3
Total volume$140K
Liquidity$54K
Event end date · UTCJan 1, 2027
Price history
Market probabilityLoading price history…
Polymarket · UTC
Sampled market observations, not AI forecasts. Lines connect available observations. Legend values are current provider quotes; chart points may be older.
Outcomes & resolution rules
1 marketThese are market-implied probabilities, not AI forecasts. A displayed quote may differ from the price available for your order.
Accepting ordersMarket odds2.5%
Hantavirus vaccine in 2026?
Yes2.5%Polymarket estimate
No97.6%Polymarket estimate
- Liquidity
- $54K
- Deadline · UTC
- Jan 1, 2027
- Yes bid / ask
- 2.3¢ / 2.6¢
- Trading fees
- Enabled · verify on Polymarket
Get the Foretrace AI forecast
See a probability estimate with uncertainty, the evidence for and against it, and a conditional decision at the available price.
Fresh successful report: 1 credit. Valid shared report: free.
Resolution rules
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.